Strengths

High TTM ROIC of 27.5% indicates ADMA converts capital into returns well above typical biotech peers, supporting stronger long-term value creation.

Balance-sheet leverage remains modest with net debt to EBITDA of 0.29x, giving ADMA more financial flexibility than many smaller plasma-derived peers.

Current and quick ratios of 7.0x and 3.8x suggest ample liquidity, reducing refinancing pressure relative to more levered specialty biologics competitors.

The business appears structurally efficient in capital deployment, because strong returns can fund growth internally more reliably than peers dependent on external capital.

Weaknesses

A cash conversion cycle of 517.6 days signals heavy working-capital intensity, which ties up cash longer than most commercial-stage peers and constrains flexibility.

Debt-to-equity of 0.50x is manageable, but it still leaves ADMA more levered than debt-light peers with stronger equity cushions.

The absence of disclosed margin metrics limits visibility into operating efficiency, making peer comparison less transparent than for larger, more mature biopharma companies.

Liquidity is strong, yet the large current asset base may partly reflect inventory and receivables buildup, which can mask underlying cash efficiency weakness.

Opportunities

If ADMA shortens its cash conversion cycle, it could release meaningful working capital and improve cash generation versus peers with similar plasma-processing models.

Further scaling of high-return invested capital could widen the gap versus lower-ROIC competitors, strengthening reinvestment capacity over the next two to five years.

A stronger liquidity position can support capacity expansion or commercial execution without immediate dilution, unlike peers that rely more heavily on equity funding.

Operational discipline in inventory and receivables management offers a direct path to improve structural efficiency, which is a key differentiator in specialty biologics.

Threats

Extended working-capital cycles expose ADMA to execution risk, because slower collections or inventory build can pressure cash flow more than at faster-turning peers.

Leverage remains moderate, so any earnings volatility could quickly weaken coverage metrics relative to larger competitors with deeper balance sheets.

Plasma-derived product markets can face supply and pricing pressure, which may compress returns and narrow ADMA's current advantage versus peers.

If competitors improve capital efficiency faster, ADMA's ROIC advantage could erode, reducing its relative positioning in a capital-intensive niche.

Overall Score

ADMA shows a structurally solid capital-return profile and liquidity position versus peers, but its very long cash conversion cycle remains the main constraint on overall positioning.